Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on March 14, 2019. The report details executive compensation adjustments and a leadership appointment approved by the Board of Directors on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation.
| Executive | Role | Annual Salary | Cash Bonus | Stock Options | RSUs |
|---|---|---|---|---|---|
| William Annett | CEO | $420,000 | $220,000 | 390,000 | 0 |
| Mitchell Levine | CFO | $346,500 | $200,000 | 245,000 | 20,000 |
| Lyndal Hesterberg | CSO | $347,280 | $311,820 | 350,000 | 0 |
Option Terms: Exercise price is $3.52 per share. Vesting is 25% after one year, with the remainder vesting monthly over 36 months. Options expire in 10 years.
RSU Terms: Granted to the CFO; vests after one year of continuous service.
Material Changes
- Leadership Appointment: Dr. Lyndal Hesterberg was promoted from Senior Vice President of Research & Development to Chief Scientific Officer.
- Compensation Increases: Significant salary increases and cash bonuses were approved for the CEO, CFO, and CSO.
- Equity Grants: Substantial stock option grants were issued to all three executives under the 2018 Equity Incentive Plan.
Outlook, Risks, and Commentary
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ from anticipated results due to risk factors detailed in the company's Form 10. The company disclaims any obligation to update these statements. No specific operational guidance or financial outlook is provided in this document.
Investor Verification Checklist
- Verify the total dilution impact of the 985,000 new stock options and 20,000 RSUs granted.
- Confirm the company's current cash position to ensure it can fund the $731,820 in immediate cash bonuses.
- Review the 2018 Equity Incentive Plan terms to understand remaining share availability.
- Check subsequent filings for any changes in the vesting schedule or employment status of the named executives.